Tags : SBRI

East of England

Mogrify secures £830k grant funding from SBRI Healthcare

Phase II funding will be used for pre-clinical assessment of regenerative cartilage therapy Follows Phase I SBRI funding, announced in April 2019 Cambridge, UK, 28 January 2020 Mogrify Ltd (Mogrify™), a UK company aiming to transform the development of cell therapies, today announced that it has secured $1.1M of additional funding from SBRI Healthcare, the NHS […]Read More


Mogrify subsidiary Chondrogenix secures funding from SBRI

Healthcare to advance regenerative cartilage therapy to the clinic Chondrogenix will use Mogrify’s data-driven conversion platform to generate a safe, efficient and scalable source of cartilage cells for the treatment of osteoarthritis Cambridge, UK, 1 st April 2019: Chondrogenix, a wholly owned subsidiary of Mogrify Ltd (Mogrify), a UK company aiming to transform the future […]Read More